Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
27/04/2026 02:20
April 27 (Reuters) - Alterity Therapeutics Ltd ATH.AX: RECEIVES POSITIVE FDA FEEDBACK ON ATH434 PHASE 3 PROGRAM IN MULTIPLE SYSTEM ATROPHY END-OF-PHASE 2 FDA MEETING REMAINS ON TRACK FOR MID-2026 Further company coverage: ATH.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alterity Therapeutics
See all newsBrief: Alterity Therapeutics Achieves Alignment With U.S. FDA On Pivotal Phase 3 Program For Ath434 In Multiple System Atrophy
Brief: Alterity Therapeutics Receives Positive FDA Feedback On Ath434 Phase 3 Program
Brief: Alterity Therapeutics Says Julian Barbaczy Appointed Non-Exec Chair
Brief: Alterity Therapeutics Raises A$20.0 Million In Strategic Placement
Brief: Alterity Therapeutics Ltd Raises A$20 Million In Capital